Decision: Favourable

Decisions Table

Study Title:

A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

  • NREC Code:

    23-NREC-CT-004

  • Decision:

    Favourable

  • Meeting Date:

    25/01/2023

  • Study Type:

    CT Application

  • Principal Investigator:

    Professor Jarushka Naidoo

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    AstraZeneca AB

Scroll to Top